Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (5282)	9/9/1998 5:20:00 PM
From: Biomaven	Read Replies (1) of 6136

V1, Considering DuPont's PE is around 30, and AGPH General probably earned around $1.50 on a pro forma basis, you can get a (non-dilutive to DD) $45 price for AGPH General before taking into account synergies. Add in a few bucks for the oncology division and you get a significant premium over the existing price. Rick Harmon first suggested the good fit with DD several weeks ago - interesting that the idea seems to be gaining credence now. Another possibility is that the tracking stock is causing shorts to cover just because they don't want to get involved with the logistics of borrowing the tracking stock and/or are they are worried that there might be a temporary squeeze because of the tracking stock mechanics. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next